Clin Cancer Res: Cabozantinib and Nivolumab in PCI-Refractory Metastatic Urothelial Carcinoma

Metastatic urothelial carcinoma (mUC) is a highly invasive malignancy with high incidence
.

Currently, the U.

FDA

The aim of this study was to evaluate the efficacy and tolerability of cabozantinib in combination with nivolumab (CaboNivo) in patients with metastatic urothelial carcinoma that has progressed after checkpoint inhibitor therapy
.

To evaluate the efficacy and tolerability of cabozantinib in combination with nivolumab (CaboNivo) in patients with metastatic urothelial carcinoma that has progressed on checkpoint inhibitor therapy

This is a phase I expansion cohort study enrolling patients with mUC who have progressed on prior immune checkpoint inhibitor therapy and are treated with cabozantinib 40 mg/day + nivolumab 3 mg/kg for 2 weeks until Disease progression or unacceptable toxicity
.

The primary endpoint was objective response rate

immunity

A total of 30 patients were recruited, 29 of whom were evaluable for efficacy
.

The median follow-up was 22.

Alleviate the situation

Alleviate the situation

The objective response rate was 16.
0%, including 1 complete response and 3 partial responses (PR)
.

Of the 4 patients who achieved remission on previous checkpoint inhibitor therapy, 2 patients were primary refractory, 1 patient achieved partial response, and 1 patient remained stable

The objective response rate was 16.

Progression-Free Survival and Overall Survival

Progression-Free Survival and Overall Survival

The median duration of response was 33.
5 months, the median progression-free survival was 3.
5 months, and the median overall survival was 10.
4 months
.

The median duration of response was 33.
5 months, the median progression-free survival was 3.
5 months, and the median overall survival was 10.
4 months median duration of response was 33.
5 months, and the median progression-free survival was 3.
5 months , the median overall survival was 10.
4 months

This research protocol decreased immunosuppressive subsets, such as regulatory T cells (treg), and increased potential antitumor immune subsets, such as atypical monocytes and effector T cells
.

At baseline, low percentages of mononuclear myeloid suppressor cells (M-MDSCs) and polymorphonuclear MDSCs, low expression of CTLA-A and TIM-3 on Treg cells, and high levels of CD4+ T cells were associated with better progression-free survival and/or overall survival

tumor immunity

In conclusion, cabozantinib combined with nivolumab had good antitumor activity and was well tolerated in patients with metastatic urothelial carcinoma refractory to immune checkpoint inhibitors

Cabozantinib combined with nivolumab has good antitumor activity in patients with immune checkpoint inhibitor-refractory metastatic urothelial carcinoma, and cabozantinib combined with nivolumab is well tolerated in patients with metastatic urothelial carcinoma.

Original source:

Daniel M.

Cabozantinib plus Nivolumab Phase I Expansion Study in Patients with Metastatic Urothelial Carcinoma Refractory to Immune Checkpoint Inhibitor Therapy Leave a Comment